In April 2026, BMS proactively entered an agreement with Dr. Reddy's Laboratories allowing for a future biosimilar version of its Orencia drug. While this manages the competitive entry, it signals the beginning of the end for Orencia's market exclusivity and future revenue erosion.
Filing excerpt
In April 2026, BMS entered into agreements with Dr. Reddy's Laboratories that allow for (i) an Orencia biosimilar for intravenous administration to be marketed in the U.S. upon approval and (ii) an Orencia biosimilar for subcutaneous administration to be marketed in the U.S. as early as February 2028.
What this signalsFilings often name leadership changes, deals and spending plans.
Competitors
Regions named
sec-10qmarketShareLossGet every 10-Q signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/85a9c18b-c8fb-4f83-9701-80af45560cd3 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "85a9c18b-c8fb-4f83-9701-80af45560cd3",
"signal_type": "sec-10q",
"signal_subtype": "marketShareLoss",
"detected_at": "2026-05-05T08:48:21.337+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "In April 2026, BMS proactively entered an agreement with Dr. Reddy's Laboratories allowing for a future biosimilar version of its Orencia drug. While this manages the competitive entry, it signals the beginning of the end for Orencia's market exclusivity and future revenue erosion.",
"metrics": {
"timeframe": "current_quarter"
},
"summary": "BMS strikes deal with Dr. Reddy's for future market entry of Orencia biosimilar",
"excerpts": "In April 2026, BMS entered into agreements with Dr. Reddy's Laboratories that allow for (i) an Orencia biosimilar for intravenous administration to be marketed in the U.S. upon approval and (ii) an Orencia biosimilar for subcutaneous administration to be marketed in the U.S. as early as February 2028.",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000010/bmy-20260331.htm",
"filing_date": "2026-04-30",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Urgency to improve",
"signal_category": "market",
"regions_mentioned": [
"United States"
],
"competitors_mentioned": [
"Dr. Reddy's Laboratories"
]
}
}
curl https://signals.autobound.ai/v1/signals/85a9c18b-c8fb-4f83-9701-80af45560cd3 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.